Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Pleiotropy01:33

Pleiotropy

40.1K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
40.1K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

8.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K
Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Background and Environment Affect Phenotype02:27

Background and Environment Affect Phenotype

6.5K
Although the genetic makeup of an organism plays a major role in determining the phenotype, there are also several environmental factors, such as temperature, oxygen availability, presence of mutagens, that can alter an organism’s phenotype.
An example of how genetic background affects phenotype can be seen in horses. The Extension gene in horses is responsible for their coat color. A wild-type gene (EE) produces black pigment in the coat, while a mutant gene (ee) produces red pigment. A...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current treatment landscape of acromegaly.

The Journal of clinical endocrinology and metabolism·2026
Same author

Familial medullary thyroid carcinoma secondary to an <i>SLC30A9</i> intragenic deletion and translation reinitiation.

medRxiv : the preprint server for health sciences·2026
Same author

Use of osilodrostat in a block-and-replace and titration strategy for cushing's syndrome: a position paper by French experts.

Reviews in endocrine & metabolic disorders·2026
Same author

Gamma knife radiosurgery vs fractionated radiotherapy : gender difference in efficacy and toxicity.

Pituitary·2026
Same author

Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome.

Endocrine reviews·2026
Same author

An update on hypophysitis.

Nature reviews. Endocrinology·2025

Related Experiment Video

Updated: Jun 10, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K

Genotype/phenotype correlations in multiple endocrine neoplasia type 2.

Frederic Castinetti1, Charis Eng2

  • 1Aix Marseille University, INSERM, MMG, Department of Endocrinology, La Conception Hospital, Assistance Publique Hopitaux de Marseille, Marseille, France.

Endocrine-Related Cancer
|October 15, 2024
PubMed
Summary

Multiple endocrine neoplasia type 2 (MEN 2), a hereditary syndrome caused by RET gene mutations, shows strong genotype-phenotype correlations. Understanding these links is key to personalizing patient management and follow-up.

Keywords:
RETmedullary thyroid cancerpheochromocytomathyroidectomy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

Related Experiment Videos

Last Updated: Jun 10, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

Area of Science:

  • Genetics
  • Endocrinology
  • Oncology

Background:

  • Multiple endocrine neoplasia type 2 (MEN 2) is a rare hereditary endocrine tumor syndrome.
  • It is caused by mutations in the rearranged during transfection (RET) gene.
  • MEN 2 presents with medullary thyroid cancer (MTC) and pheochromocytoma.

Purpose of the Study:

  • To discuss the main genotype-phenotype correlations in MEN 2.
  • To explore potential factors influencing these correlations.
  • To improve individualized management and follow-up for MEN 2 patients.

Main Methods:

  • Review of existing literature on RET gene mutations and their clinical manifestations in MEN 2.
  • Analysis of genotype-phenotype correlations, focusing on MTC onset and pheochromocytoma penetrance.
  • Discussion of potential modifying factors beyond specific RET variants.

Main Results:

  • Specific RET mutations are strongly associated with MTC onset age and pheochromocytoma risk.
  • Highest/high-risk RET variants can lead to early-onset MTC, guiding optimal thyroidectomy timing.
  • Variability in MTC aggressiveness and pheochromocytoma presence suggests other modifying factors.

Conclusions:

  • Genotype-phenotype correlations in MEN 2 are crucial for predicting disease risk and timing interventions.
  • Further research into modifying factors is needed to fully individualize patient care.
  • Understanding these complex interactions will optimize management strategies for MEN 2.